Drug Discovery

Patrick Vallance, President - R&D, GlaxoSmithKline said the company is looking forward to more collaborations and is looking at a number of options to move ahead with its expansion plans.

Dr Reddy's Labs to buy IP rights of fondaparinux

Australian drug discovery and development company Alchemia Ltd has entered into an agreement for sale of exclusive intellectual property rights of fondaparinux sodium to Dr Reddy's Laboratories (DRL), for USD 17.5 million.

Dr Reddy's ink pact with Purdue varsity for drug research

According to a statement issued by the University, the intent of the MoU is to forge a strong strategic partnership in a range of research areas and novel technologies in the field of pharmaceutical processes and product development.

SPARC to raise Rs 250 crore through rights issue

Sun Pharma Advanced Research Company was demerged from Sun Pharma as a pharma research and drug discovery company in 2007. Shares of SPARC closed at Rs 379.50 per scrip on the BSE, down 4.05 per cent from the previous close.

SPARC net loss widens to Rs 9.40 crore in Q4

Total income of the company decreased to Rs 43.13 crore in the quarter ended March 31, 2015 compared with Rs 45.21 crore in the corresponding period last fiscal.

MPI Research, inviCRO, & 3D Imaging announce partnership

MPI Research, is pleased to announce a strategic partnership with inviCRO and 3D Imaging to unite world-class molecular imaging, radiochemistry, and informatics to accelerate drug discovery and development.

Jubilant Life to split business into two subsidiaries

Board of Directors of the company at its meeting held on May 28, 2013 has accorded its approval to consolidate its pharmaceutical segment under two separate verticals, Jubilant Life Sciences said in a filing to BSE.

Advinus, Takeda Pharma initiate drug discovery

Advinus Therapeutics Ltd (Advinus)and Japanese firm Takeda Pharmaceutical Company Ltd (Takeda) jointly announced today that they have entered into an agreement to initiate a three-year drug discovery collaboration.

Piramal's quest for a blockbuster drug

When most pharmas are shying away from high-risk drug discovery, Piramal Healthcare is going for it full steam. Has it found a new way?

Piramal board approves demerger of New Chemical Entity

The board of Piramal Healthcare has approved the demerger of the New Chemical Entity from Piramal Life Sciences and merging it into itself. Shareholders will be issues one share of parent Piramal Healthcare for every four shares of Life Sciences.